Right now, the world is in a real race to produce the Coronavirus vaccine. Several are the fronts that are carrying out studies and tests so that this objective is achieved safely. As an example, we have the vaccine developed by the University of Oxford in partnership with the Oswaldo Cruz Foundation (Fiocruz). In addition to this, another one is also in the final testing phase, the Chinese vaccine Sinovack Biotec, which has the help of the Butantan Institute in Brazil.
According to research, we can say that we are relatively close to the production of a safe vaccine. The Ipsos Institute conducted the study “Global Attitudes on a COVID-19 Vaccine”, with 27 countries for the world economic Forum. This work showed that the global average of people who would be willing to be immunized is 74%. Brazil positioned itself in this ranking in 2nd place, together with Australia, countries in which 88% of the population was willing to take the vaccine against Coronavirus.
HSR Health also conducted a survey in Brazil, seeking to understand the behavior of the population in relation to the distribution of immunization. In all, 1509 people were interviewed, from all states in the age group of 18 to 65 years. The study showed that 67% prefer to wait for the SUS vaccination schedule (Unified Health System – free public service in Brazil) and only 33% would seek immediate access in private clinics. However, only 38% of respondents believe that SUS is prepared to serve the entire population, while 64% see private clinics as more capable.
But we have the question: would the Brazilian pay for a vaccine against COVID-19? That same research shows that yes! 80% of the population does not rule out the idea of paying between R $ 50 to R $ 99 for immunization. Very interesting data to consider from now on access and consumption fronts. However, for Bruno Mattos, director of HSR Health, as a matter of habit, the demand for access to the vaccine in SUS would be 2/3 of the population and only about 33% would actually pay. Still, it is of great value to consider the percentage of possible paying consumers of the vaccine. A significant portion of the consumer market, at this time, can be of great value when carrying out campaigns to promote the drug in the country.
When it comes to research in Brazil, did you know that we at ABMR are experts in the health and pharmaceutical research segment? More than 50% of our client portfolio today is in this segment. This means that precision in results and experience in carrying out projects with doctors, patients and healthcare professionals from the most diverse specialties and the pharmaceutical industry throughout Latin America is our expertise. So, if your project is in this area, talk to us by clicking here!
Count on us as your project partner with special conditions for you.